diaendoСахарный диабетDiabetes mellitus2072-03512072-0378Endocrinology research centre10.14341/2072-0351-5523diaendo-5523Research ArticleСтатьиArticlesСтатины и риск развития сахарного диабетаStatin use and risk of diabetes mellitusДрапкинаОксана МихайловнаDrapkinaOksana Mikhailovnadrapkina@bk.ruКостюкевичМарина ВикторовнаKostyukevichMarina Viktorovna-ГБОУ ВПО Первый Московский государственный медицинский университет им. И.М. Сеченова, МоскваI.M. Sechenov First Moscow State Medical University, Moscow201215062012152№2 (2012)7782Copyright © Драпкина О.М., Костюкевич М.В., 20122012Драпкина О.М., Костюкевич М.В.Drapkina O.M., Kostyukevich M.V.Данная работа распространяется под лицензией Creative Commons Attribution 4.0.This work is licensed under a Creative Commons Attribution 4.0 License.https://www.dia-endojournals.ru/jour/article/view/5523

В настоящее время с целью модификации липидного профиля используются 4 группы препаратов: секвестранты желчныхкислот, никотиновая кислота, производные фиброевой кислоты и статины.В течение последних лет активно обсуждается вопрос о возможном увеличении риска развития сахарного диабета 2 типа(СД2) на фоне лечения статинамиЕдиного мнения относительно механизма влияния статинов на развитие СД не существует.Спорным остается вопросможно ли считать снижение чувствительности к инсулину под влиянием статинов их класс-эффектом.Статины несомненно являются препаратами первого ряда у пациентов с выраженной дислипидемией, требующей меди-каментозного лечения, однако не улучшают чувствительность к инсулину, более того, в ряде исследований применениестатинов было связано с повышенным риском возникновения СД2. У пациентов относящихся к группе риска по развитиюСД, целесообразно кроме назначения статинов, также рассматривать возможность комбинированной терапии, в томчисле с применением бигуанидов.

At present time four groups of medications are used to correct dyslipidemia: bile acid sequestrants, niacin, fibric acid derivatives andstatins. During last years statins' potential to increase risk of type 2 diabetes mellitus (T2DM) is actively discussed, though no commonopinion about the possible mechanism of such effect has evolved as yet. Insulin desensitizing effect as a class feature of statins remainsa disputable question.Position of statins as a first-line therapy for severe hyperlipidemia seems undoubted; however they do not improve insulin sensitivity.Moreover, several studies reported increased risk of T2DM. It is feasible to consider combined treatment (including metformin) inpatients from risk groups for development of T2DM, receiving statins

статиныинсулинорезистентностьсахарный диабетатеросклерозметформинstatinsinsulin resistancediabetes mellitusatherosclerosismetforminReferencesExpert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 May 1;285(19):2486-2497.Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive Summary of the Third Report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel III). JAMA. 2001 May 1;285(19):2486-2497.Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006 Jan;99(1):1-14.Rizzo M, Berneis K. Low-density lipoprotein size and cardiovascular risk assessment. QJM. 2006 Jan;99(1):1-14.Ohmura C, Watada H, Hirose T, Tanaka Y, Kawamori R. Acute onset and worsening of diabetes concurrent with administration of statins. Endocr J. 2005 Jun;52(3):369-372.Ohmura C, Watada H, Hirose T, Tanaka Y, Kawamori R. Acute onset and worsening of diabetes concurrent with administration of statins. Endocr J. 2005 Jun;52(3):369-372.Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001 Jan 23;103(3):357-362.Freeman DJ, Norrie J, Sattar N, Neely RD, Cobbe SM, Ford I, Isles C, Lorimer AR, Macfarlane PW, McKillop JH, Packard CJ, Shepherd J, Gaw A. Pravastatin and the development of diabetes mellitus: evidence for a protective treatment effect in the West of Scotland Coronary Prevention Study. Circulation. 2001 Jan 23;103(3):357-362.Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008 May;31(5):982-988. Epub 2008 Jan 30.Gupta AK, Dahlof B, Dobson J, Sever PS, Wedel H, Poulter NR; Anglo-Scandinavian Cardiac Outcomes Trial Investigators. Determinants of new-onset diabetes among 19,257 hypertensive patients randomized in the Anglo-Scandinavian Cardiac Outcomes Trial--Blood Pressure Lowering Arm and the relative influence of antihypertensive medication. Diabetes Care. 2008 May;31(5):982-988. Epub 2008 Jan 30.Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-1158).Sever PS, Dahlöf B, Poulter NR, Wedel H, Beevers G, Caulfield M, Collins R, Kjeldsen SE, Kristinsson A, McInnes GT, Mehlsen J, Nieminen M, O'Brien E, Ostergren J; ASCOT investigators. Prevention of coronary and stroke events with atorvastatin in hypertensive patients who have average or lower-than-average cholesterol concentrations, in the Anglo- Scandinavian Cardiac Outcomes Trial--Lipid Lowering Arm (ASCOT-LLA): a multicentre randomised controlled trial. Lancet. 2003 Apr 5;361(9364):1149-1158).Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-1504. Epub 2004 Mar 8.Cannon CP, Braunwald E, McCabe CH, Rader DJ, Rouleau JL, Belder R, Joyal SV, Hill KA, Pfeffer MA, Skene AM; Pravastatin or Atorvastatin Evaluation and Infection Therapy-Thrombolysis in Myocardial Infarction 22 Investigators. Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes. N Engl J Med. 2004 Apr 8;350(15):1495-1504. Epub 2004 Mar 8.Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease-a perspective. Drug Des Devel Ther. 2010 Dec 9;4:383-413.Kones R. Rosuvastatin, inflammation, C-reactive protein, JUPITER, and primary prevention of cardiovascular disease-a perspective. Drug Des Devel Ther. 2010 Dec 9;4:383-413.Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb. 2006 Jun;13(3):123-9.Sasaki J, Iwashita M, Kono S. Statins: beneficial or adverse for glucose metabolism. J Atheroscler Thromb. 2006 Jun;13(3):123-9.Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, Sachdeva R, Kesan SH, Mehta JL. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med. 2009 Mar;57(3):495-499.Sukhija R, Prayaga S, Marashdeh M, Bursac Z, Kakar P, Bansal D, Sachdeva R, Kesan SH, Mehta JL. Effect of statins on fasting plasma glucose in diabetic and nondiabetic patients. J Investig Med. 2009 Mar;57(3):495-499.Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55:1209-1216.Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Shin EK. Atorvastatin causes insulin resistance and increases ambient glycemia in hypercholesterolemic patients. J Am Coll Cardiol. 2010;55:1209-1216.Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract. 2009 Sep;63(9):1308-1313.Kostapanos MS, Milionis HJ, Agouridis AD, Rizos CV, Elisaf MS. Rosuvastatin treatment is associated with an increase in insulin resistance in hyperlipidaemic patients with impaired fasting glucose. Int J Clin Pract. 2009 Sep;63(9):1308-1313.Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010 Feb 27;375(9716):735-742. Epub 2010 Feb 16.Sattar N, Preiss D, Murray HM, Welsh P, Buckley BM, de Craen AJ, Seshasai SR, McMurray JJ, Freeman DJ, Jukema JW, Macfarlane PW, Packard CJ, Stott DJ, Westendorp RG, Shepherd J, Davis BR, Pressel SL, Marchioli R, Marfisi RM, Maggioni AP, Tavazzi L, Tognoni G, Kjekshus J, Pedersen TR, Cook TJ, Gotto AM, Clearfield MB, Downs JR, Nakamura H, Ohashi Y, Mizuno K, Ray KK, Ford I. Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials. Lancet. 2010 Feb 27;375(9716):735-742. Epub 2010 Feb 16.Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010 Jan;87(1):98-107. Epub 2009 Nov 12.Baker WL, Talati R, White CM, Coleman CI. Differing effect of statins on insulin sensitivity in non-diabetics: a systematic review and meta-analysis. Diabetes Res Clin Pract. 2010 Jan;87(1):98-107. Epub 2009 Nov 12.Oldfield E. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside.Acc Chem Res. 2010 Sep 21;43(9):1216-1226.Oldfield E. Targeting isoprenoid biosynthesis for drug discovery: bench to bedside.Acc Chem Res. 2010 Sep 21;43(9):1216-1226.Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 2001 Nov 2;507(3):357-361.Chamberlain LH. Inhibition of isoprenoid biosynthesis causes insulin resistance in 3T3-L1 adipocytes. FEBS Lett. 2001 Nov 2;507(3):357-361.Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T.Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006 Aug;49(8):1881-1892. Epub 2006 May 10.Nakata M, Nagasaka S, Kusaka I, Matsuoka H, Ishibashi S, Yada T.Effects of statins on the adipocyte maturation and expression of glucose transporter 4 (SLC2A4): implications in glycaemic control. Diabetologia. 2006 Aug;49(8):1881-1892. Epub 2006 May 10.Brozinick JT Jr, Berkemeier BA, Elmendorf JS. "Acting" on GLUT4: Membrane & Cytoskeletal Components of Insulin Action. Curr Diabetes Rev. 2007 May; 3(2): 111-122.Brozinick JT Jr, Berkemeier BA, Elmendorf JS. "Acting" on GLUT4: Membrane & Cytoskeletal Components of Insulin Action. Curr Diabetes Rev. 2007 May; 3(2): 111-122.Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, Shin EK. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009 Jun;204(2):483-490. Epub 2008 Sep 27.Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, Shin EK. Differential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009 Jun;204(2):483-490. Epub 2008 Sep 27.Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, Shin EKDifferential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009 Jun;204(2):483-90. Epub 2008 Sep 27.Koh KK, Quon MJ, Han SH, Lee Y, Kim SJ, Park JB, Shin EKDifferential metabolic effects of pravastatin and simvastatin in hypercholesterolemic patients. Atherosclerosis. 2009 Jun;204(2):483-90. Epub 2008 Sep 27.Devaraj S, Siegel D, Jialal I. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol. 2007 Nov 1;100(9):1397-1399. Epub 2007 Aug 16.Devaraj S, Siegel D, Jialal I. Simvastatin (40 mg/day), adiponectin levels, and insulin sensitivity in subjects with the metabolic syndrome. Am J Cardiol. 2007 Nov 1;100(9):1397-1399. Epub 2007 Aug 16.Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucoseinduced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205-1213.Yada T, Nakata M, Shiraishi T, Kakei M. Inhibition by simvastatin, but not pravastatin, of glucoseinduced cytosolic Ca2+ signalling and insulin secretion due to blockade of L-type Ca2+ channels in rat islet beta-cells. Br J Pharmacol 1999;126:1205-1213.Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193-203. Epub 2008 Oct 22.Nathan DM, Buse JB, Davidson MB, Ferrannini E, Holman RR, Sherwin R, Zinman B; American Diabetes Association; European Association for Study of Diabetes. Medical Management of Hyperglycemia in Type 2 Diabetes: A Consensus Algorithm for the Initiation and Adjustment of Therapy. A consensus statement of the American Diabetes Association and the European Association for the Study of Diabetes. Diabetes Care. 2009 Jan;32(1):193-203. Epub 2008 Oct 22.NICE clinical guideline 87. Type 2 diabetes: the management of type 2 diabetes. National Institute for Health and Clinical Excellence; 2009.NICE clinical guideline 87. Type 2 diabetes: the management of type 2 diabetes. National Institute for Health and Clinical Excellence; 2009.Lima LM, Wiernsperger N, Kraemer-Aguiar LG, Bouskela E. Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen. Clinics (Sao Paulo). 2009 May;64(5):415-420.Lima LM, Wiernsperger N, Kraemer-Aguiar LG, Bouskela E. Short-term treatment with metformin improves the cardiovascular risk profile in first-degree relatives of subjects with type 2 diabetes mellitus who have a metabolic syndrome and normal glucose tolerance without changes in C-reactive protein or fibrinogen. Clinics (Sao Paulo). 2009 May;64(5):415-420.de Aguiar LG, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N, Bottino D, Bouskela E. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care. 2006 May;29(5):1083-1089.de Aguiar LG, Bahia LR, Villela N, Laflor C, Sicuro F, Wiernsperger N, Bottino D, Bouskela E. Metformin improves endothelial vascular reactivity in first-degree relatives of type 2 diabetic patients with metabolic syndrome and normal glucose tolerance. Diabetes Care. 2006 May;29(5):1083-1089.Implications of the United Kingdom. Prospective Diabetes Study. American Diabetes Association. Diabetes Care, Volume 25, Supplement 1, January 2002.Implications of the United Kingdom. Prospective Diabetes Study. American Diabetes Association. Diabetes Care, Volume 25, Supplement 1, January 2002.

The authors declare that there are no conflicts of interest present.